Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia
| Autor: | Steven Fishbane, Geoffrey A. Block, Pablo E. Pergola, Lisa C. Loram, Katrin Uhlig, John F. Neylan, Glenn M. Chertow |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male medicine.medical_specialty Anemia 030232 urology & nephrology 030204 cardiovascular system & hematology Placebo Gastroenterology Ferric Compounds law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Double-Blind Method law Clinical Research Internal medicine medicine Humans Renal Insufficiency Chronic Adverse effect Aged Aged 80 and over Anemia Iron-Deficiency business.industry General Medicine Iron deficiency Middle Aged medicine.disease Tolerability Iron-deficiency anemia Nephrology Female Hemoglobin business |
| Zdroj: | Journal of the American Society of Nephrology : JASN. 28(6) |
| ISSN: | 1533-3450 |
| Popis: | Iron deficiency anemia is common and consequential in nondialysis-dependent CKD (NDD-CKD). Efficacy and tolerability of conventional oral iron supplements are mixed; intravenous iron administration associates with finite but important risks. We conducted a randomized double-blind clinical trial in adults with NDD-CKD and iron deficiency anemia to compare the safety and efficacy of oral ferric citrate (n=117) and placebo (n=115). The primary end point was the proportion of patients who achieved a ≥1.0 g/dl increase in hemoglobin at any time during a 16-week randomized period. Patients who completed the 16-week period could also participate in an 8-week open-label extension period. Significantly more patients randomized to ferric citrate achieved the primary end point (61 [52.1%] versus 22 [19.1%] with placebo; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|